Efimosfermin alfa

DRUG7 trials

Sponsors

GlaxoSmithKline

Conditions

Liver Diseases, AlcoholicMetabolic Dysfunction-associated SteatohepatitisNon-alcoholic Fatty Liver Disease

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/\u200bEuropean Ancestry

CompletedNCT07335198

GlaxoSmithKlineNon-alcoholic Fatty Liver Disease

Start: 2026-03-05End: 2026-08-13Updated: 2026-09-15

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

RecruitingNCT07358546

GlaxoSmithKlineNon-alcoholic Fatty Liver Disease

Start: 2026-03-13End: 2027-10-13Target: 32Updated: 2026-06-09

Phase 2

A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)

RecruitingNCT07791043

GlaxoSmithKlineLiver Diseases, Alcoholic

Start: 2026-08-31End: 2030-01-14Target: 274Updated: 2026-09-17

Phase 3

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

RecruitingNCT07221188

GlaxoSmithKlineNon-alcoholic Fatty Liver Disease

Start: 2025-12-12End: 2028-03-24Target: 1250Updated: 2026-09-17

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

RecruitingNCT07221227

GlaxoSmithKlineNon-alcoholic Fatty Liver Disease

Start: 2025-10-24End: 2031-12-12Target: 1200Updated: 2026-07-27

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

RecruitingNCT07701993

GlaxoSmithKlineMetabolic Dysfunction-associated Steatohepatitis

Start: 2026-07-22End: 2033-08-24Target: 1740Updated: 2026-09-18

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

RecruitingNCT07704892

GlaxoSmithKlineMetabolic Dysfunction-associated Steatohepatitis

Start: 2026-07-22End: 2033-12-08Target: 380Updated: 2026-09-18